ESC 365 - Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial

HFA Premium Access

Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial

Session: Young Investigator Award: clinical research

Topic: Pharmacotherapy

Speaker: Doctor J. Butt (Copenhagen, DK)

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

1 presentation

0 follower

3 more presentations in this session

Discontinuation of guideline-recommended heart failure treatments after a first hospitalization for heart failure - An analysis from the SwedeHF registry

Distinct pathophysiological pathways in women and men with heart failure

Speaker: Doctor A. Ravera (Brescia, IT)

The effect of dapagliflozin according to iron status and its effect on iron metabolism: insights from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)

Access the full session

Young Investigator Award: clinical research

Speakers: Doctor J. Butt, Doctor A. Ravera, Doctor K. Docherty

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources